-
1.发明公开公开(公告)号：US20240140938A1
公开(公告)日：2024-05-02
申请号：US18257133
申请日：2021-12-17
发明人： Jianming Bao , Chen Cheng , Faben A. Cruz , Yeon-Hee Lim , Cedric L. Hugelshofer , Jinlong Jiang , Victor W. Mak , Emma Helen Southgate
IPC分类号： C07D409/14 , C07D409/12
CPC分类号： C07D409/14 , C07D409/12
摘要： Invented are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.
-
2.发明授权公开(公告)号：US11976061B2
公开(公告)日：2024-05-07
申请号：US17494906
申请日：2021-10-06
发明人： Yeon-Hee Lim , Eric R. Ashley , Jianming Bao , Chen Cheng , James P. Roane , Emma Helen Southgate
IPC分类号： C07D409/14 , C07D235/26 , C07D405/12 , C07D409/12 , C07D417/14 , C07D471/04
CPC分类号： C07D409/14 , C07D235/26 , C07D405/12 , C07D409/12 , C07D417/14 , C07D471/04
摘要： Invented are compounds of Formula I
and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.
-
搜索结果
2 条记录 (耗时 0.01 秒)
